Lisanti Capital Growth LLC Buys 13,175 Shares of Vaxcyte, Inc. (NASDAQ:PCVX)

Lisanti Capital Growth LLC raised its stake in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 68.1% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 32,515 shares of the company's stock after buying an additional 13,175 shares during the quarter. Lisanti Capital Growth LLC's holdings in Vaxcyte were worth $3,715,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. China Universal Asset Management Co. Ltd. raised its holdings in Vaxcyte by 68.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 21,466 shares of the company's stock worth $2,453,000 after acquiring an additional 8,685 shares in the last quarter. Harbor Capital Advisors Inc. increased its stake in shares of Vaxcyte by 392.4% during the 2nd quarter. Harbor Capital Advisors Inc. now owns 40,342 shares of the company's stock worth $3,046,000 after purchasing an additional 32,149 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its stake in Vaxcyte by 18.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,176,181 shares of the company's stock valued at $216,966,000 after purchasing an additional 498,359 shares during the last quarter. Swiss National Bank grew its holdings in Vaxcyte by 20.4% during the first quarter. Swiss National Bank now owns 178,000 shares of the company's stock worth $12,159,000 after purchasing an additional 30,100 shares during the period. Finally, Russell Investments Group Ltd. acquired a new position in Vaxcyte during the first quarter worth approximately $1,288,000. Institutional investors and hedge funds own 96.78% of the company's stock.

Insider Buying and Selling at Vaxcyte

In related news, CEO Grant Pickering sold 15,000 shares of the company's stock in a transaction on Friday, August 23rd. The stock was sold at an average price of $78.98, for a total transaction of $1,184,700.00. Following the completion of the sale, the chief executive officer now directly owns 478,888 shares in the company, valued at $37,822,574.24. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In related news, CEO Grant Pickering sold 15,000 shares of the firm's stock in a transaction on Friday, August 23rd. The stock was sold at an average price of $78.98, for a total transaction of $1,184,700.00. Following the sale, the chief executive officer now owns 478,888 shares of the company's stock, valued at $37,822,574.24. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Andrew Guggenhime sold 42,000 shares of the business's stock in a transaction on Friday, October 18th. The stock was sold at an average price of $115.39, for a total value of $4,846,380.00. Following the sale, the chief financial officer now owns 90,383 shares in the company, valued at $10,429,294.37. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 117,464 shares of company stock valued at $12,640,276. 3.10% of the stock is currently owned by corporate insiders.

Vaxcyte Price Performance

Vaxcyte stock traded down $3.03 during mid-day trading on Monday, reaching $103.64. 846,283 shares of the company were exchanged, compared to its average volume of 839,763. The firm has a market cap of $12.92 billion, a PE ratio of -23.19 and a beta of 1.01. The company has a fifty day simple moving average of $111.56 and a 200-day simple moving average of $87.61. Vaxcyte, Inc. has a 12 month low of $46.16 and a 12 month high of $121.06.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last announced its quarterly earnings data on Tuesday, November 5th. The company reported ($0.83) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.10) by $0.27. During the same quarter last year, the company earned ($0.91) EPS. Sell-side analysts anticipate that Vaxcyte, Inc. will post -4.14 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on PCVX. Jefferies Financial Group lifted their target price on Vaxcyte from $108.00 to $129.00 and gave the stock a "buy" rating in a research note on Tuesday, September 3rd. BTIG Research raised their target price on shares of Vaxcyte from $98.00 to $160.00 and gave the stock a "buy" rating in a research note on Tuesday, September 3rd. Mizuho boosted their price objective on Vaxcyte from $113.00 to $163.00 and gave the stock an "outperform" rating in a report on Tuesday, September 10th. Leerink Partners increased their target price on Vaxcyte from $106.00 to $153.00 and gave the stock an "outperform" rating in a research note on Tuesday, September 3rd. Finally, Needham & Company LLC restated a "buy" rating and issued a $140.00 price target on shares of Vaxcyte in a research note on Wednesday, November 6th. Seven research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $147.50.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.